Qifang Long*, Weipei Zhu*, Jundong Zhou†, Jinchang Wu†, Weixian Lu‡, Cui Zheng‡, Dongmei Zhou‡, Ling Yu‡, Ru Yang‡
Oncology Research, Vol.25, No.4, pp. 595-603, 2017, DOI:10.3727/096504016X14765492198706
Abstract Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide.
Cancer stem cells (CSCs) have been identified in ovarian cancer and other malignant tumors as a small
population of cells that are capable of self-renewal and multidifferentiation. CD133+
ovarian CSCs have been
reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged
as one of the most promising therapeutic markers for ovarian cancer treatment. In the current study, we constructed a recombinant adenovirus Cre/loxP regulation system to selectively introduce truncated Bid (tBid)
expression specifically… More >
Login
Register
